Online Crowdfunding for Urologic Cancer Care
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cohen, A.J.; Brody, H.; Patino, G.; Ndoye, M.; Liaw, A.; Butler, C.; Breyer, B.N. Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care. JAMA Intern. Med. 2019, 179, 1717–1720. [Google Scholar] [CrossRef] [PubMed]
- Song, S.; Cohen, A.J.; Lui, H.; Mmonu, N.A.; Brody, H.; Patino, G.; Liaw, A.; Butler, C.; Fergus, K.B.; Mena, J.; et al. Use of GoFundMe® to crowdfund complementary and alternative medicine treatments for cancer. J. Cancer Res. Clin. Oncol. 2020, 146, 1857–1865. [Google Scholar] [CrossRef] [PubMed]
- Zenone, M.; Snyder, J.; Caulfield, T. Crowdfunding Cannabidiol (CBD) for Cancer: Hype and Misinformation on GoFundMe. Am. J. Public Health 2020, 110, S294–S299. [Google Scholar] [CrossRef] [PubMed]
- Rajwa, P.; Hopen, P.; Mu, L.; Paradysz, A.; Wojnarowicz, J.; Gross, C.P.; Leapman, M.S. Online Crowdfunding Response to Coronavirus Disease 2019. J. Gen. Intern. Med. 2020, 35, 2482–2484. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef]
- Imber, B.S.; Varghese, M.; Ehdaie, B.; Gorovets, D. Financial toxicity associated with treatment of localized prostate cancer. Nat. Rev. Urol. 2019, 17, 28–40. [Google Scholar] [CrossRef]
- Casilla-Lennon, M.M.; Choi, S.K.; Deal, A.M.; Bensen, J.T.; Narang, G.; Filippou, P.; McCormick, B.; Pruthi, R.; Wallen, E.; Tan, H.-J.; et al. Financial Toxicity among Patients with Bladder Cancer: Reasons for Delay in Care and Effect on Quality of Life. J. Urol. 2018, 199, 1166–1173. [Google Scholar] [CrossRef]
- Ramsey, S.D.; Bansal, A.; Fedorenko, C.R.; Blough, D.K.; Overstreet, K.A.; Shankaran, V.; Newcomb, P. Financial Insolvency as a Risk Factor for Early Mortality Among Patients with Cancer. J. Clin. Oncol. 2016, 34, 980–986. [Google Scholar] [CrossRef]
- Niedzwiedz, C.L.; Knifton, L.; Robb, K.A.; Katikireddi, S.V.; Smith, D.J. Depression and anxiety among people living with and beyond cancer: A growing clinical and research priority. BMC Cancer 2019, 19, 943. [Google Scholar] [CrossRef]
- Park, J.; Look, K.A. Health Care Expenditure Burden of Cancer Care in the United States. Inquiry 2019, 56, 46958019880696. [Google Scholar] [CrossRef]
- Holler, J.T.; Hakam, N.; Nabavizadeh, B.; Sadighian, M.J.; Shibley, W.P.; Li, K.D.; Weiser, L.; Rios, N.; Enriquez, A.; Leapman, M.S.; et al. Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urol. Pract. 2022, 9, 56–63. [Google Scholar] [CrossRef]
- Di Carlo, A.; Leveridge, M.; McGregor, T.B. Crowdfunding in urology: Canadian perspective. Can. Urol. Assoc. J. 2020, 15, E139–E143. [Google Scholar] [CrossRef]
- Arnastauskaitė, J.; Ruzgas, T.; Bražėnas, M. An Exhaustive Power Comparison of Normality Tests. Mathematics 2021, 9, 788. [Google Scholar] [CrossRef]
- Balakrishnan, N.; Brito, M.R.; Quiroz, A.J. On the goodness-of-fit procedure for normality based on the empirical characteristic function for ranked set sampling data. Metrika 2013, 76, 161–177. [Google Scholar] [CrossRef]
- King, G.; Zeng, L. Logistic Regression in Rare Events Data. Political Anal. 2001, 9, 137–163. [Google Scholar] [CrossRef]
- Loeb, S.; Taneja, S.; Walter, D.; Zweifach, S.; Byrne, N. Crowdfunding for prostate cancer and breast cancer. Br. J. Urol. 2018, 122, 723–725. [Google Scholar] [CrossRef]
- Thomas, H.S.; Lee, A.W.; Nabavizadeh, B.; Namiri, N.K.; Hakam, N.; Martin-Tuite, P.; Rios, N.; Enriquez, A.; Mmonu, N.A.; Cohen, A.J.; et al. Characterizing online crowdfunding campaigns for patients with kidney cancer. Cancer Med. 2021, 10, 4564–4574. [Google Scholar] [CrossRef]
- Kaddas, H.K.; Pannier, S.T.; Mann, K.; Waters, A.R.; Salmon, S.; Tsukamoto, T.; Warner, E.L.; Fowler, B.; Lewis, M.A.; Fair, D.B.; et al. Age-Related Differences in Financial Toxicity and Unmet Resource Needs Among Adolescent and Young Adult Cancer Patients. J. Adolesc. Young Adult Oncol. 2020, 9, 105–110. [Google Scholar] [CrossRef]
- Fong, A.; Jain, M.; Sacks, W.; Ho, A.; Chen, Y. Crowdfunding Campaigns and Thyroid Surgery: Who, What, Where, and How Much? J. Surg. Res. 2020, 253, 63–68. [Google Scholar] [CrossRef]
- Akiki, R.K.; Borrelli, M.R.; Kwan, D. Online Crowdfunding Enables Patients’ Access to Gender-Affirming Surgery. Transgender Health 2021, 6, 240–243. [Google Scholar] [CrossRef]
- Nolte, A.C.; Nguyen, K.A.; Perecman, A.; Katz, M.S.; Kenney, P.A.; Cooperberg, M.R.; Gross, C.P.; Leapman, M.S. Association Between Twitter Reception at a National Urology Conference and Future Publication Status. Eur. Urol. Focus 2021, 7, 214–220. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.B.; Park, H.S.; Gross, C.P.; Yu, J. Use of Alternative Medicine for Cancer and Its Impact on Survival. J. Natl. Cancer Inst. 2018, 110, 121–124. [Google Scholar] [CrossRef] [PubMed]
Characteristic | Overall | Cancer Type | p-Value | |||
---|---|---|---|---|---|---|
N = 2126 | Bladder, N = 568 (27%) | Kidney, N = 579 (27%) | Prostate, N = 372 (17%) | Testicular, N = 607 (29%) | ||
Campaigns from US | 2016 (95%) | 527 (93%) | 557 (96%) | 362 (97%) | 570 (94%) | 0.005 |
Goal amount ($) | 10,000 (5000–25,000) | 10,000 (5000–20,000) | 12,525 (7500–25,000) | 10,727 (5000–25,000) | 10,000 (5500–20,000) | 0.004 |
Amout collected ($) | 5208 (2565–11,315) | 4062 (2284–8570) | 5810 (2628–13,272) | 5233 (2171–12,255) | 6005 (3285–11,090) | <0.001 |
% Goal collected | 0.50 (0.24–0.84) | 0.41 (0.19–0.73) | 0.51 (0.24–0.83) | 0.44 (0.19–0.80) | 0.60 (0.33–0.95) | <0.001 |
Sucessfull campain (goal reached) | 363 (17%) | 73 (13%) | 92 (16%) | 57 (15%) | 141 (23%) | <0.001 |
Campaign days running | 920 (573–1336) | 926 (589–1342) | 870 (556–1302) | 835 (553–1271) | 1018 (619–1384) | 0.001 |
Amount collected per day ($) | 6 (3–12) | 5 (2–9) | 6 (3–15) | 6 (2–14) | 6 (3–12) | <0.001 |
Donors No. | 57 (31–111) | 42 (24–80) | 63 (34–137) | 49 (22–106) | 72 (43–125) | <0.001 |
Amount collected per donor ($) | 91 (69–122) | 98 (73–127) | 92 (69–120) | 100 (69–139) | 83 (66–109) | <0.001 |
Shares No. | 421 (208–781) | 284 (152–554) | 482 (246–863) | 370 (137–686) | 546 (320–976) | <0.001 |
Amount collected per share ($) | 13 (7–26) | 14 (8–27) | 13 (7–27) | 16 (9–30) | 12 (7–21) | <0.001 |
Followers No. | 60 (32–115) | 43 (26–84) | 64 (36–138) | 51 (23–109) | 76 (46–127) | <0.001 |
Updates No. | 2 (0–5) | 2 (0–5) | 2 (0–7) | 2 (0–5) | 2 (0–6) | 0.3 |
Description length (words) | 248 (159–392) | 234 (148–360) | 249 (160–418) | 254 (156–427) | 255 (168–382) | 0.051 |
Female | 360 (17%) | 165 (29%) | 195 (34%) | 0 (0%) | 0 (0%) | <0.001 |
Histology provided | 379 (18%) | 94 (17%) | 165 (28%) | 30 (8.1%) | 90 (15%) | <0.001 |
First-person description | 245 (12%) | 47 (8.3%) | 63 (11%) | 61 (16%) | 74 (12%) | 0.002 |
Religious references | 878 (41%) | 220 (39%) | 258 (45%) | 163 (44%) | 237 (39%) | 0.10 |
Children mentions | 972 (46%) | 310 (55%) | 264 (46%) | 206 (55%) | 192 (32%) | <0.001 |
Relationship status provided | 930 (44%) | 274 (48%) | 213 (37%) | 177 (48%) | 266 (44%) | <0.001 |
Job status provided | 985 (46%) | 274 (48%) | 253 (44%) | 130 (35%) | 328 (54%) | <0.001 |
Family status provided | 1602 (75%) | 385 (68%) | 487 (84%) | 258 (69%) | 472 (78%) | <0.001 |
Photos No. | 1.00 (1.00–3.00) | 1.00 (1.00–3.00) | 1.00 (1.00–3.00) | 2.00 (1.00–4.00) | 1.00 (1.00–2.00) | <0.001 |
Family photo provided | 1071 (50%) | 281 (49%) | 287 (50%) | 189 (51%) | 314 (52%) | 0.8 |
Un-/underinsurance mentions | 623 (29%) | 180 (32%) | 165 (28%) | 131 (35%) | 147 (24%) | 0.001 |
Fundraising for treatment | 703 (34%) | 140 (25%) | 219 (41%) | 134 (36%) | 210 (36%) | <0.001 |
Fundraising for treatment & living expenses | 985 (48%) | 290 (52%) | 251 (47%) | 169 (46%) | 275 (47%) | 0.13 |
Fundraising only for living expenses | 358 (17%) | 124 (22%) | 67 (12%) | 68 (18%) | 99 (17%) | <0.001 |
No data/Not applicable | 80 | |||||
Fundrising for alternative treatment | 79 (5.6%) | 22 (6.1%) | 3 (0.8%) | 52 (22%) | 2 (0.4%) | <0.001 |
Fundraising for conventional treatment | 1256 (89%) | 312 (87%) | 356 (94%) | 153 (65%) | 435 (97%) | <0.001 |
Fundraising for conventional & alternative treatment | 83 (5.9%) | 25 (7.0%) | 19 (5.0%) | 29 (12%) | 10 (2.2%) | <0.001 |
No data/Not applicable | 708 | |||||
Localized disease | 183 (14%) | 57 (20%) | 72 (19%) | 27 (12%) | 27 (6.1%) | <0.001 |
Nonlocalized disease | 1147 (86%) | 232 (80%) | 306 (81%) | 192 (88%) | 417 (94%) | <0.001 |
No data on cancer advancement | 796 | |||||
Fundraising for surgery | 977 (58%) | 260 (60%) | 293 (62%) | 86 (28%) | 338 (70%) | <0.001 |
Fundraising for chemotherapy | 851 (50%) | 234 (54%) | 161 (34%) | 79 (26%) | 377 (78%) | <0.001 |
Fundraising for radiation therapy | 254 (15%) | 53 (12%) | 87 (19%) | 80 (26%) | 34 (7.0%) | <0.001 |
Fundraising for immunotherapy | 109 (6.5%) | 49 (11%) | 49 (10%) | 8 (2.6%) | 3 (0.6%) | <0.001 |
n (%); Median (IQR) |
Characteristic | Overall | Treatment Type | p-Value | ||
---|---|---|---|---|---|
N = 1418 | Alternative, N = 79 (5.6%) | both, N = 83 (5.9%) | Conventional, N = 1256 (89%) | ||
Cancer Type | <0.001 | ||||
Bladder | 359 (25%) | 22 (28%) | 25 (30%) | 312 (25%) | |
Kidney | 378 (27%) | 3 (3.8%) | 19 (23%) | 356 (28%) | |
Prostate | 234 (17%) | 52 (66%) | 29 (35%) | 153 (12%) | |
Testicular | 447 (32%) | 2 (2.5%) | 10 (12%) | 435 (35%) | |
Campaigns from US | 1351 (95%) | 76 (96%) | 72 (87%) | 1203 (96%) | 0.003 |
Goal amount ($) | 12,500 (7500–25,000) | 25,000 (15,750–40,000) | 25,000 (12,500–50,000) | 10,000 (7000–25,000) | <0.001 |
Amount collected ($) | 5732 (2845–12,102) | 8527 (4762–16,206) | 11,000 (4830–20,702) | 5362 (2708–11,334) | <0.001 |
% Goal collected | 48 (23–83) | 41 (17–72) | 41 (19–75) | 49 (24–84) | 0.038 |
Successful campain (goal reached) | 231 (16%) | 6 (7.6%) | 9 (11%) | 216 (17%) | 0.031 |
Campaing days running | 944 (581–1348) | 1049 (685–1378) | 1025 (670–1306) | 928 (571–1348) | 0.3 |
Amount collected per day ($) | 6 (3–13) | 9 (6–18) | 10 (5–25) | 6 (3–12) | <0.001 |
Donors No. | 61 (33–115) | 76 (38–124) | 89 (50–143) | 59 (32–113) | 0.006 |
Amount collected per donor ($) | 93 (70–125) | 124 (99–195) | 111 (86–156) | 91 (69–119) | <0.001 |
Shares No. | 443 (236–813) | 456 (177–712) | 584 (292–938) | 431 (236–806) | 0.017 |
Amount collected per share ($) | 13 (7–26) | 23 (13–35) | 19 (9–32) | 13 (7–24) | <0.001 |
Followers No. | 63 (35–117) | 76 (39–118) | 86 (51–146) | 61 (34–116) | 0.023 |
Updates No. | 2.0 (1.0–6.0) | 3.0 (1.0–6.5) | 2.0 (1.0–6.5) | 2.0 (1.0–6.0) | 0.2 |
Description lenght | 276 (180–424) | 317 (223–584) | 359 (208–534) | 268 (178–413) | <0.001 |
Female | 238 (17%) | 7 (8.9%) | 14 (17%) | 217 (17%) | 0.2 |
Histology provided | 288 (20%) | 9 (11%) | 15 (18%) | 264 (21%) | 0.10 |
First-person description | 180 (13%) | 17 (22%) | 19 (23%) | 144 (11%) | <0.001 |
Religious references | 597 (42%) | 38 (48%) | 38 (46%) | 521 (41%) | 0.4 |
Children mentions | 613 (43%) | 36 (46%) | 50 (60%) | 527 (42%) | 0.005 |
Relationship status provided | 611 (43%) | 38 (48%) | 44 (53%) | 529 (42%) | 0.10 |
Job status provided | 665 (47%) | 30 (38%) | 28 (34%) | 607 (48%) | 0.009 |
Family status provided | 1050 (74%) | 49 (62%) | 69 (83%) | 932 (74%) | 0.009 |
Photos No. | 1 (1–3) | 2.00 (1–5) | 2 (1–4) | 1 (1–3) | 0.004 |
Family photo provided | 695 (49%) | 35 (44%) | 46 (55%) | 614 (49%) | 0.4 |
Un-/uninsurance mention | 500 (35%) | 42 (53%) | 42 (51%) | 416 (33%) | <0.001 |
Fundraising only for treatment | 591 (42%) | 50 (63%) | 44 (53%) | 497 (40%) | <0.001 |
Fundraising for treatment and living expenses | 827 (58%) | 29 (37%) | 39 (47%) | 759 (60%) | <0.001 |
Localized disease | 144 (15%) | 7 (13%) | 4 (6.2%) | 133 (16%) | 0.089 |
Nonlocalized disease | 802 (85%) | 47 (87%) | 61 (94%) | 694 (84%) | 0.089 |
Fundraising for surgery | 977 (69%) | 0 (0%) | 42 (51%) | 935 (74%) | <0.001 |
Fundraising for chemotherapy | 851 (60%) | 0 (0%) | 40 (48%) | 811 (65%) | <0.001 |
Fundraising for radiation therapy | 254 (18%) | 0 (0%) | 17 (20%) | 237 (19%) | <0.001 |
Fundraising for immunotherapy | 109 (7.7%) | 0 (0%) | 17 (20%) | 92 (7.3%) | <0.001 |
n (%); Median (IQR) |
Campaigns Reaching Goal Amount (Successful Campaigns) | ||||||
Characteristic | Univariable Analysis | Multivariable Analysis | ||||
OR | 95% CI | p-Value | OR | 95% CI | p-Value | |
Cancer | ||||||
Bladder | Ref. | Ref. | Ref. | Ref. | ||
Kidney | 1.28 | 0.92–1.78 | 0.144 | 1.37 | 0.88–2.15 | 0.161 |
Prostate | 1.23 | 0.84–1.78 | 0.281 | 1.41 | 0.84–2.34 | 0.189 |
Testicular | 2.05 | 1.51–2.80 | <0.001 | 2.03 | 1.34–3.11 | <0.001 |
Description (per 100 words) | 0.96 | 0.92–1.01 | 0.010 | - | ||
Shares (per 100) | 1.02 | 1.01–1.03 | 0.003 | 1.03 | 1.01–1.05 | <0.001 |
Updates | 1.01 | 1.00–1.01 | 0.254 | - | ||
Days running (per 100) | 1.02 | 0.99–1.04 | 0.167 | - | ||
Religious references | 0.73 | 0.57–0.92 | 0.007 | 0.79 | 0.58–1.06 | 0.118 |
Treatment | ||||||
Conventional | Ref | Ref. | Ref. | |||
Alternative | 0.43 | 0.17–0.89 | 0.022 | 0.51 | 0.20–1.13 | 0.099 |
Both | 0.61 | 0.29–1.16 | 0.142 | 0.76 | 0.35–1.47 | 0.431 |
Children mentions | 0.69 | 0.55–0.87 | 0.002 | 0.95 | 0.68–1.34 | 0.787 |
Family status | 0.75 | 0.59–0.97 | 0.028 | 0.78 | 0.54–1.12 | 0.175 |
Job status | 1.11 | 0.89–1.39 | 0.366 | - | ||
Un-/underinsurance | 0.70 | 0.53–0.90 | 0.006 | 0.83 | 0.61–1.14 | 0.251 |
Provided data on cancer advancement | 0.78 | 0.62–0.98 | 0.032 | 0.75 | 0.55–1.02 | 0.067 |
Nonlocalized cancer | 1.25 | 0.81–2.02 | 0.317 | - | ||
Provided data on cancer histology | 0.82 | 0.60–1.11 | 0.195 | - | ||
Model AUC 0.628 | ||||||
Campaigns Reaching Goal Amount (Higest Quartile; >11,310$) | ||||||
Univariable Analysis | Multivariable Analysis | |||||
Characteristic | OR | 95% CI | p-Value | OR | 95% CI | p-Value |
Cancer | ||||||
Bladder | Ref. | Ref. | ||||
Kidney | 1.92 | 1.46–2.54 | <0.001 | 1.28 | 0.80–2.07 | 0.294 |
Prostate | 1.84 | 1.36–2.51 | <0.001 | 0.96 | 0.56–1.63 | 0.871 |
Testicular | 1.45 | 1.10–1.93 | 0.009 | 0.98 | 0.62–1.57 | 0.948 |
Description (per 100 words) | 1.14 | 1.10–1.18 | <0.001 | 1.08 | 1.02–1.14 | 0.004 |
Shares (per 100) | 1.13 | 1.11–1.15 | <0.001 | 1.13 | 1.10–1.16 | <0.001 |
Updates | 1.03 | 1.02–1.04 | <0.001 | 1.00 | 0.98–1.02 | 0.823 |
Days running (per 100) | 1.04 | 1.02–1.06 | <0.001 | 1.01 | 0.98–1.04 | 0.595 |
Religious references | 1.02 | 0.84–1.25 | 0.82 | - | ||
Treatment | ||||||
Conventional | Ref. | Ref. | ||||
Alternative | 2.04 | 1.27–3.23 | 0.003 | 2.56 | 1.33–4.99 | 0.005 |
Both | 2.91 | 1.86–4.55 | <0.001 | 2.15 | 1.22–3.79 | 0.009 |
Children mentions | 1.13 | 0.92–1.37 | 0.237 | - | ||
Family status | 1.49 | 1.17–1.91 | 0.001 | 1.36 | 0.92–2.04 | 0.119 |
Job status | 1.07 | 0.88–1.30 | 0.512 | - | ||
Un-/underinsurance | 0.90 | 0.72–1.11 | 0.332 | - | ||
Nonlocalized disease | 2.40 | 1.57–3.69 | <0.001 | 2.37 | 1.38–4.06 | 0.001 |
Provided data on cancer histology | 1.13 | 0.88–1.45 | 0.342 | - | ||
Model AUC: 0.764 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rajwa, P.; Hopen, P.; Wojnarowicz, J.; Kaletka, J.; Paszkiewicz, I.; Lach-Wojnarowicz, O.; Mostafaei, H.; Krajewski, W.; D’Andrea, D.; Małkiewicz, B.; et al. Online Crowdfunding for Urologic Cancer Care. Cancers 2022, 14, 4104. https://doi.org/10.3390/cancers14174104
Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Mostafaei H, Krajewski W, D’Andrea D, Małkiewicz B, et al. Online Crowdfunding for Urologic Cancer Care. Cancers. 2022; 14(17):4104. https://doi.org/10.3390/cancers14174104
Chicago/Turabian StyleRajwa, Pawel, Philip Hopen, Jakub Wojnarowicz, Julia Kaletka, Iga Paszkiewicz, Olga Lach-Wojnarowicz, Hadi Mostafaei, Wojciech Krajewski, David D’Andrea, Bartosz Małkiewicz, and et al. 2022. "Online Crowdfunding for Urologic Cancer Care" Cancers 14, no. 17: 4104. https://doi.org/10.3390/cancers14174104